Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 26, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of specific share transactions and does not contain financial performance data.
Material Changes
No material changes to the company's financial position or operations are reported. The filing details specific share movements on September 18, 2006:
- 112 Ordinary shares were sold on behalf of a participant in the GlaxoSmithKline Annual Investment Plan at GBP 14.6233 per share.
- 162 Ordinary shares were transferred from the SmithKline Beecham Employee Benefit Trust to a participant in the Annual Investment Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It notes that the SmithKline Beecham Employee Benefit Trust is a discretionary fund for non-US employees and former employees. Director Mr. J Heslop is noted as having an interest in shares held in the fund consistent with other non-US employees. The transactions were notified in accordance with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the specific share price of GBP 14.6233 for the September 18, 2006 transaction.
- Confirm the total volume of shares (112 sold, 162 transferred) associated with the Annual Investment Plan.
- Review the role of the SmithKline Beecham Employee Benefit Trust in relation to Director Mr. J Heslop's interests.